The new guidelines for the use of monoclonal antibodies (MABs) published in neurodegenerative diseases serve as exemplary clinical recommendations for clinical physicians and health care providers, supporting the progress of the treatment of Alzheimer’s disease in Switzerland.
The Swiss Memory Memory (SMC) network, a team of specialized clinics in Switzerland that diagnose and cure patients with dementia, has released new national guidelines for the use of anti-amyloids MAB-such as Lecanemab and Donanemab-to treat Alzheimer’s disease in Switzerland. Lecanemab is now authorized by the European Commission under strict conditions.
Published in Issue 11 April 2025 Neurodegenerative diseasesA Karger magazine, paper represents a coordinated effort by the SMC network to ensure the safe, effective and moral application of these emerging therapies. By serving as a clinical practice guide for clinical doctors and healthcare providers, it facilitates the application of emerging therapeutic options in the field of Alzheimer’s disease.
The document describes the criteria for the selection of patients, the confirmation of the biomarker, the genotype APOE, the monitoring of Aria through MRI and the infrastructure required to support the safe delivery of treatment. It also emphasizes the importance of up -to -date consent and recommends the creation of a national register of patients.
The guidelines come from interdisciplinary discussions between clinical doctors on the SMC-Network Network, Geriatrics, Old Psychiatrists, Neuropsychologists, Neurosologists and Patient Organizations, including representatives of academic and non-academics.
In a joint statement, the lead writers Dr. Med Ansgar Felbecker and Professor Giovanni B. Frisoni commented: “We have created a team of experts to provide recommendations in Switzerland for when to use anti-amyloid monoclonal antibodies in the care of patients with Alzheimer’s disease.
While the document provides a specific framework for the use of MAB in the routine clinic, the authors hope that as Alzheimer’s disease is taking care of a new therapeutic era, these guidelines can balance innovation with clinical responsibility-promoting a model.
It is great that the magazine Neurodegenerative diseases serves as a home for such important guidance that has the ability to affect thousands of patients, “
Professor Gilles Allali, editor -in -chief of his leader Neurodegenerative diseases, Publishers
“The latest guidelines submitted by Swiss experts really have the ability to turn the care of Alzheimer’s disease around the world.”
